MAPT and Alzheimer disease: In the current study, we have learned from this approach that Alzheimer disease aggregates, purified by affinity to antibodies against total tau or Aβ1–42/APP, are distinguished by several proteins that are specific to one type of aggregate, but nevertheless have in common the great majority of contributing proteins.